Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 3 Completed 347 enrolled AbbVie Paragon Biomedical · collab

RandomizedParallel-groupTriple-blindTreatment

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

Evaluation	Drug	Modality	Dose	Route
Comparator	Etanercept	Protein / enzyme biologic	50 mg	Subcutaneous
Subject	briakinumab	Monoclonal antibody	100 mg	Subcutaneous